With the advancement of personalized cancer immunotherapies, new tools are needed to identify tumor antigens and evaluate T-cell responses in model systems, specifically those that exhibit clinically relevant tumor progression. Key transgenic mouse models of breast cancer are generated and maintained on the FVB genetic background, and one such model is the mouse mammary tumor virus-polyomavirus middle T antigen (MMTV-PyMT) mousean immunocompetent transgenic mouse that exhibits spontaneous mammary tumor development and metastasis with high penetrance. Backcrossing the MMTV-PyMT mouse from the FVB strain onto a C57BL/6 genetic background, in order to leverage well-developed C57BL/6 immunological tools, results in delayed tumor development and variable metastatic phenotypes.
Introduction
The success of cancer immunotherapies has shed considerable light on the ability of the host immune system to survey and eliminate aberrant tumor cells. Pivotal to such therapies is the ability of the immune system to specifically recognize the tumor, a process that occurs at the immunological synapse when the T-cell receptor (TCR) of cytotoxic T lymphocytes (CTLs) binds to tumor-specific intracellular peptides presented by major histocompatibility complex (MHC) class I molecules. Such peptides can be derived from pathogen, host, or mutated-self proteins, the latter being classified as tumor neoantigens. Recognition of these peptide-MHC (pMHC) complexes by TCRs is a prerequisite for T-cell activation and tumor cell elimination.
This mechanism is so critical to anti-tumor immunity that successful CTL responses against tumor neoantigens can induce long-term remission in a subset of patients with melanoma [1, 2] .
Unfortunately, many cancers, including breast cancers, have low mutation burdens and/or "cold" immunologic microenvironments and, so far, have responded poorly to immunotherapy [3] .
Thus, advanced tools, such as immune-competent mouse models of breast cancer, are needed for studying how antigen-specific CTL responses are regulated in breast and other cancers.
The mouse mammary tumor virus-polyomavirus middle T antigen (MMTV-PyMT) transgenic mouse is widely used for studying breast cancer because tumors arise with high penetrance, spontaneously metastasize to the lungs, and exhibit clinically relevant histology in the FVB/NJ background [4] . Other well-established breast cancer models (MMTV-Neu, MMTV-c-Myc, MMTV-Wnt1) are also found in the FVB strain, in large part due to the technical feasibility of introducing transgenes into this strain [5] . Given the centrality of the FVB mouse to in vivo breast cancer studies, the ability to track antigen-specific T-cell responses would be 4 transformative to the utility of these murine models. Here we address this issue by combining proteomics and in silico MHC immunology technology to develop a tool that allows accurate prediction of tumor peptides presented on MHC class I in the FVB mouse.
Peptides that are recognized by T cells, termed T-cell epitopes, vary depending on which class I MHC molecule presents the peptide. Murine strains possess different class I haplotypes with different peptide binding preferences [6] . In mice, the class I MHC α-chain proteins are encoded by H-2K and H-2D. In FVB and BALB/c mouse strains, a duplication event of the H-2D locus spawned the pseudogene H-2L, although the physiological relevance of this duplication remains unknown [7] . Because of this, we have focused our efforts on H-2K and H-2D peptide prediction. The FVB strain expresses the H-2 q haplotype and, despite the preponderance of FVB mice in disease models, the MHC peptide binding motifs of the H-2 q molecules are understudied [8] . To address this paucity of data and the difficulties in studying immune responses in the FVB strain, we DNA sequenced the cDNA forms of H-2D q and H-2K q gene transcripts and transfected H-2D q and H-2K q gene constructs to facilitate high-throughput proteomic identification of >8500 peptides presented by MHC molecules of the H-2 q haplotype. This data allowed us to develop an online mouse H-2 pan-specific prediction toolthat is, a prediction tool encompassing the H-2 b , H-2 d , H-2 k , and H-2 q haplotypes.
A pan-specific neural network method that uses pooled data from multiple MHC molecules, as opposed to a single allele, greatly improves predictive power and accuracy [9] . We have also shown that a model integrating peptide binding affinity data with eluted ligand data achieves highly improved predictive performance when it comes to the identification of eluted ligands and 5 T-cell epitopes [10] . Thus, the H-2D q and H-2K q peptide elution data were combined with peptide binding and eluted ligand data from other murine haplotypes (H-2 b , H-2 d , H-2 k ). The resulting prediction tool is tailored to the "q" haplotype but allows cancer immunobiologists to accurately predict peptides of other murine class I haplotypes. We named this tool "NetH2pan", as an extension of our other published predictive tools (NetMHCpan). Prior to this, NetMHCpan was the only murine prediction tool available for the H-2 q haplotype. NetMHCpan, however, could only predict H-2 q ligands based on MHC sequence homology to other haplotypes.
NetH2pan improves upon this tool by incorporating eluted peptide data from the H-2 q haplotype.
To validate this pan-specific algorithm, we eluted >2000 H-2 q peptides from class I MHC on MMTV-PyMT primary tumor cells, identifying peptides derived from 27 cancer-associated source proteins. We confirmed that the NetH2pan prediction tool successfully predicts cancerassociated tumor peptide ligands with high fidelity (top 1%), providing a significant improvement to current murine peptide prediction tools. The combined molecular, proteomic, and in silico MHC strategies described here empower a new generation of cancer immunotherapy research in murine models of breast cancer. 
Materials & Methods

H-2K and H-2D sequencing of the FVB strain
High-resolution MHC typing was performed by Sequence Based Typing (SBT) at the University of Oklahoma Health Science Center CLIA/ASHI-accredited HLA typing laboratory on FVB mouse spleens. Extracted RNA (converted to cDNA), was amplified with two pairs of primers specific for the 5' and 3' UTRs of H-2K and H-2LD loci. H-2L and H-2D coamplification was dissected using locus-specific sequencing primers. Primers and nucleotide/protein sequences have been deposited to GenBank (accession numbers MF352192, MF352193).
Cell lines, transfection, and production of MHC complexes for elution studies
HeLa cells were purchased from ATCC, immediately expanded, and frozen per manufacturer's instructions. 721.221 cells were a kind gift from Dr. Ted Hansen (Washington University, St. Louis). HeLa and 721.221 cells were authenticated by in-house HLA-typing and confirmed with known HLA-types of the original cells. Cells were re-authenticated after transfection with soluble MHC (sMHC) constructs and prior to seeding in roller bottles. Soluble MHC constructs were generated as previously described with the addition of a very low-density lipoprotein receptor (VLDLr) purification tag [11] . 721.221 and HeLa cells were stably transfected with the sMHC by nucleofection per the manufacturer's cell-line optimized protocols (nucleofection kits R and V, Lonza), G418 drug selection for 10 days, and subcloned by single-cell sorting. sMHCproducing clones were identified using a capture enzyme-linked immunosorbent assay (ELISA) with anti-VLDLr (CRL-2197 hybridoma, ATCC) as the capture antibody and anti-β 2microglobulin (DAKO) as the detection antibody, and developed with o-phenylenediamine dihydrochloride (Sigma). Transfected cells were seeded into 48 roller bottles and sMHCcontaining supernatant was collected. sMHC was purified from the supernatant using affinity 7 chromatography with an antibody to VLDLr as published [12] . Complexes were eluted from the column in 0.2 N acetic acid and immediately processed for isolation of the peptide ligands
Liquid Chromatography-Mass Spectrometry (LC-MS) of H-2D q and H-2K q peptides
Peptide ligands were eluted as described previously [1, 11] . Briefly, peptides were separated from purified MHC with acid boil followed by 3-kDa ultrafiltration (Merck Millipore). Peptides were fractionated with reverse phase-high performance liquid chromatography (RP-HPLC) then analysed by LC-MS. Nano-scale LC was performed with an Eksigent nano-LC-400 with an Eksigent autosampler (AB SCIEX). Fractions were combined with internal retention time (iRT, Biognosys) peptides before injection. Eluate was ionized with a NanoSpray III ion source (AB Sciex), and MS1 and MS2 fragment spectra were obtained in data dependent acquisition (DDA) mode using a SCIEX TripleTOF 5600. Peptide sequences were obtained from spectra using 
Training a pan-specific murine MHC ligand prediction method
Assembling a panel of peptide-H-2 binding and elution data
The amino-acid sequences of the H-2D q and H-2K q molecules were aligned to a reference database of MHC sequences to determine the pseudo-sequence of MHC residues in direct contact with the peptide, as described in detail previously [13] . Both for H-2-D q and H-2K q on April 19, 2018. © 2018 American Association for Cancer Research. cancerimmunolres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on April 3, 2018; DOI: 10.1158/2326-6066.CIR-17-0298 elution data sets, potential contaminants and false positives (1-5% of the ligands) were filtered out using GibbsCluster [14] , applying the default parameters suggested for MHC I ligands of variable length. Binding affinity and ligand elution data for seven additional murine MHC molecules (H-2D b , D d , K b , K d , K k , L d , and L q ) were obtained from the IEDB [15] , and consisted of 9,625 pMHC binding affinity measurements and 3,310 eluted ligands of length 8 to 11 residues. Binding affinity values aff in IC 50 nM were rescaled using the relationship t = 1log(aff)/log(50,000) ensuring that target values fell between 0 and 1 [16] . Because elution experiments only report positive peptides, negative instances must be generated artificially: for each H-2 molecule, the peptide length with the highest number N of observed ligands was determined, introducing then a flat distribution of 10*N random natural peptides for each of the lengths 8, 9, 10 and 11 as artificial negatives. Each training point is therefore represented by a triplet consisting of 1) the peptide sequence; 2) the MHC pseudo-sequence associated with the peptide; and 3) the target value, either as a rescaled binding affinity or as a binary value (one for observed ligand, zero for artificial negative).
Neural network training
A neural network ensemble was trained in 5-fold cross-validation as described [9] , extending the architecture of the neural network with a second output neuron [10] . This addition allows combining heterogeneous training data by utilizing the first output neuron (and its connections from the hidden layer) for binding affinity examples, and the second output neuron to predict ligands. Because the weights between input and hidden layers are shared between the two data types, motifs can be learned and reinforced within and between data types. All other parameters were consistent with the architecture of NetMHCpan-3.0: networks were initialized with ten on April 19, 2018. © 2018 American Association for Cancer Research. cancerimmunolres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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alternative random configurations of weights, using a single hidden layer composed of either 56 or 66 neurons and representing peptides and pseudo-sequences using BLOSUM encoding [9] .
Up to one insertion and two deletions were allowed to accommodate peptides of lengths 8 to 11 to a common alignment core of nine amino acids. Additional features encoded as input to the networks included the length of the insertion/deletion (if any) and the length of the peptide. The training set for H-2D q included only the ligands derived from HeLa cells; ligands eluted from 721.221 cells were reserved as an independent set to evaluate the performance of the predictor.
Predictive performance was calculated in terms of Area under the ROC curve (AUC) and in
Positive Predictive Value (PPV). In line with previous work, the predictions on the ligand data sets were compared against a decoy set of 999 natural random peptides for each positive instance, equally distributed across the four peptide lengths 8, 9, 10 and 11 [17] . 
Length and motif preferences of H-2 molecules
For each MHC molecule included in the model, 400,000 random natural peptides (100,000 for each of the lengths 8, 9, 10, 11) were submitted to the neural networks and ranked by ligand prediction score. The relative frequency of each peptide length among the top 1% scoring peptides was then used to draw the ligand length profile characterizing each H-2 molecule.
Similarly, the same top 1% scoring peptides were used to generated sequence motifs of the MHC molecules included in the model using the software Seq2Logo [18] . For the analysis of the peptide cleavage preferences, ligands were mapped back to the non-redundant UniProtKB/Swiss-Prot database [19] to retrieve their source protein sequences. Enrichment scores M in the peptide flanking regions were then calculated as M=log 2 (F i,A /E A ), where F i,A is the frequency of amino acid A at position i, and E A is the expected frequency for amino acid A calculated on all source proteins containing at least one ligand.
Mice
Female, five-to-eight week old FVB/NJ (Jackson Laboratories Stock Number 001800) and MMTV-PyMT (Jackson Laboratories Stock Number 002374) mice were purchased from Jackson Laboratories. All animal work was in accordance with policies at the University of Utah, and all studies were approved by the University of Utah IACUC committee. MMTV-PyMT tumor cells were harvested from MMTV-PyMT transgenic mice, collagenase digested, and implanted into cleared mammary fat pads according to standard procedures [20] . Tumors were measured weekly and size was calculated using length and width calliper measurements in the ellipsoid formula (Tumor volume = 1/2(length × width 2 )). Mice were euthanized when tumors reached a maximum of 2cm 3 and tumors were flash frozen in liquid nitrogen for peptide extraction.
Peptide identification from MMTV-PyMT tumors
Anti-H-2D q (28-14-8S hybridoma, ATCC) and anti-H-2K q (34-1-2S hybridoma, ATCC) were used to generate H-2 q immunoaffinity columns by coupling to CNBR-activated Sepharose 4 Fast Flow (GE Healthcare, Sweden). Peptides were extracted based on a previously published protocol ( Supplementary Fig. S1 ) [21] . Whole tumors were flash frozen in liquid nitrogen, cryogenically milled (MM400, RETSCH), suspended in lysis buffer containing octylphenoxy poly(ethyleneoxy)ethanol (IGEPAL) (Sigma) and cOmplete EDTA-free protease inhibitor cocktails (Roche), and clarified by ultracentrifugation. Filtered lysate was passed over sequential anti-H-2D q and H-2K q columns. Peptides were eluted in acid and boiled, isolated by RP-HPLC, and analysed by LC/MS using DDA mode for de novo peptide identification as described above.
The UniProt database with Mus Musculus taxonomy was used as a reference library for fragments. Peptide results can be accessed through the IEDB (Submission ID 1000724, http://www.iedb.org).
Results
Characterization of H-2 q haplotype
We began by sequencing the class I MHC H-2 q loci with high-resolution MHC typing. The sequencing strategy employed here amplified the regions flanked by the 5' and 3' UTRs for H-2K and H-2L/D genes of the FVB/NJ strain. Locus-specific oligonucleotide primers were used to separate the H-2D sequence from H-2L. The amplification primers and nucleotide sequences for H-2D q and H-2K q have been deposited into GenBank (accession numbers MF352192, MF352193). The H-2L locus, although expressed in the "q" haplotype, is only present in a few MHC haplotypes [6] , and we therefore chose to characterize only H-2D q and H-2K q . The resulting sequences for H-2 q loci differed by 2 and 1 amino acids from previous reports for H-2K q and H-2D q , respectively, a finding that is expected given strain-to-strain variation and improved sequencing techniques. Having determined the sequence of H-2D q and H-2K q , we proceeded to identify peptides presented by the "q" haplotype. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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Using the MHC class I H-2K q and H-2D q sequences, we designed sMHC constructs that lacked the transmembrane domain and incorporated a VLDLr purification tag. Engineered purification tags (e.g., VLDLr) eliminated the need for allele specific antibodies (28-14-8S and 34-1-2S) that may cross-react with other alleles within the same haplotype, allowing isolation of only the peptide:MHC complexes of interest. For alleles in which the motif is not yet characterized, such an approach allowed the characterization of the correct motifs with high confidence. sMHCbound peptidomes accurately represent the full-length, membrane-bound peptidomes with comparable binding motifs, peptide lengths, predicted binding antigens, and putative source antigens [22] . Based on these findings, sMHC is a valuable and physiologically relevant tool for Analysis using Seq2Logo revealed a MHC binding motif for each allele (Fig. 1A and B ) [18] .
H-2D q favored proline at P2 and hydrophobic residues at PΩ whereas H-2K q favored acidic P2 residues and a hydrophobic PΩ ( Fig. 1A and B ). The ligand length preference differed substantially between the two loci -H-2D preferred 9-mers, whereas H-2K bound predominately 8mers (Fig. 1C) . These ligands were derived from 4000 source proteins, and most source proteins provided a single peptide (Fig. 1D ).
Generation of a prediction model for murine MHC class I
Pooling this large set of H-2D q and H-2K q ligands with publicly available H-2 ligand elution and binding affinity data, we generated a pan-specific prediction model applicable to nine different mouse MHC molecules. This combination of multiple molecules and data types produced a consistently high performance in terms of AUC for the prediction of binding affinity (BA) and ligand likelihood (EL), even for alleles for which only one data type was available ( Table 1) . Of particular interest for this study, the predictor obtains a remarkably high cross-validated AUC = 0.993 for H-2D q . An alternative useful performance metric is the positive predictive value (PPV), which measures the fraction of true positives in the top P p % predicted ligands. Because each MHC molecule is expected to present approximately one out of one-thousand peptides in the proteome, the PPV was calculated on the top P p = 0.1% predictions. The PPV for the five H-2 alleles characterized by ligand data varied between 35.7% and 61.1%, with an average of 49.8%
( Supplementary Table S1 ) [15, 17] . The model maintains a high predictive performance on H- 2D q ligands eluted from another cell line (721.221) that were not included in the original training set (AUC = 0.944, PPV = 59.7%). Ligands detected in both the HeLa and 721.221 cell lines (see Supplementary Fig. S2 ) were excluded from this validation. When both affinity and ligand elution data were available for a given allele, the combined model did not benefit from the added binding affinity data to predict eluted ligands, compared to a model only trained on eluted ligands (Table 1 ). However, in cases in which only binding affinity or eluted ligand data were available for a given allele, the combined approach had the advantage of complementing one data type with the other, using a single, unified model. The prediction tool can be accessed at http://www.cbs.dtu.dk/services/NetMHCpan-4.0/NetH2pan/.
The eluted and predicted binding motifs for H-2K q and H-2D q both show a preference for hydrophobic residues in the PΩ F pocket ( Fig. 1A and B ; Fig. 2A and B ). This hydrophobic amino acid preference is highly conserved amongst murine and human MHC and is essential for stability within the MHC class I-binding cleft [23] . The second anchor for H-2D q is a proline at the P2 B pocket. The H-2K q allele, on the other hand, favours peptides with acidic residues at the P2 anchor. The preference for acidic residues at P2 could not be captured by networks trained without H-2K q eluted ligands. Despite the ability of pan-specific methods to infer binding motifs by similarity to other alleles, dissimilar molecules can be hard to predict. As a rule of thumb, the pan-specific method described here performed accurately for alleles with a distance D (measured in terms of the pseudo sequence similarity) to the training data lower than 0.1 [24] . In the An important feature of neural networks trained on peptides of variable length is their ability to assimilate the ligand length preferences of MHC molecules [25] . Accounting for MHCdependent length preferences has important implications when scanning for potential ligands in epitope discovery. In this respect, the model shows that H-2K q has a marked preference for 8mers (Fig. 2C ), reflecting the distribution directly observed in the elution experiments (Fig. 1C) .
This tendency is similar to the length preference for H-2K b , both as predicted by our model and as described in the literature [26] . H-2D q has a more canonical peptide length distribution, centered on 9mers and to a lesser extent on 10mers and 11mers (Fig. 1C, 2C) . These data confirm that the prediction tools accurately represent the peptide dataset and that this panspecific approach can identify subtle differences in length and anchor preferences of the murine MHC Class I.
Cytoplasmic proteins targeted for degradation undergo antigen processing (defined by proteasomal cleavage, trimming by cytosolic peptidases, and N-terminal processing by endoplasmic reticulum aminopeptidases). Given this, we hypothesized that certain residues would be favored in the source protein regions directly surrounding the MHC presented ligands.
Analysis of flanking source protein sequences revealed a preference for methionine (M) at N-1, whereas proline (P) was disfavored at both termini (N-1, C+1) ( Fig. 2D ). Positively charged residues (R, K) appeared to be enriched at C+1, C+2, whereas negatively charged residues (D, E) were depleted in these positions. The source proteins of H-2 ligands extracted from the IEDB ( Fig. 2E, element- [17] had similar patterns. To test whether these cleavability preferences could improve the identification of H-2 ligands, we re-trained NetH2pan including the 5-residue regions flanking the ligands as additional input features. We did not observe a significant impact of cleavability preferences in cross-validated performance, with average AUC increasing slightly from 0.945 (model without flanking sequences) to 0.947 (with flanks), and PPV decreasing from 49.8% to 49.1% ( Supplementary Table S2 ). On the H-2D q evaluation set from 721.221 cells, AUC increased from 0.944 to 0.945, and PPV from 59.7% to 60.5%. Although signatures of peptide processing were found consistently across data sets and MHC alleles, their contribution thus did not appear to be beneficial to improving ligand prediction.
Tumor antigen discovery validation of the NetH2pan algorithm
Finally, we sought to validate the NetH2pan prediction tool on ligands directly eluted from primary murine tumors as a complementary method to eliminate any bias introduced by the sMHC approach. The ability of NetH2pan to predict peptides presented on full length H-2D q and H-2K q via physiological antigen processing would provide important validation of this tool.
Since aberrancies to MHC class I presentation varies among tumor models, and functions as a mechanism of tumor immune evasion, we confirmed class I MHC expression on >60% of EpCAM + primary tumor cells using flow cytometry ( Supplementary Fig. S3 ). These percentages correlate with global MHCI transcript expression in healthy mammary tissue and secondary lymphoid organs in mice [27] . Compared with splenocytes, tumor cells exhibited heterogeneous MHC class I protein expression ( Supplementary Fig. S3E ). We next purified class I MHC from the five grams of murine tumors; we were able to purify >2000 H-2 q ligands from MMTV-PyMT tumors. These findings suggest that the ability for MMTV-PyMT tumors to thrive in the FVB Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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Peptide:MHC complexes were extracted from MMTV-PyMT tumors pooled from seven mice, based on a previously published protocol ( Supplementary Fig. S1 ) [21] . Whole tumors were flash frozen in liquid nitrogen, cryogenically milled, and suspended in lysis buffer. Lysates were clarified by ultracentrifugation and passed over sequential H-2D q and H-2K q columns. Peptides were eluted by acid boil, and the yield of MHC was quantified by the β-2-microglobulin peak in first dimension HPLC (pH 2.85). Peptides were fractionated and analyzed by LC/MS using Data Dependent Acquisition (H-2D q and H-2K q ) for de novo peptide identification. Full length purification relied on two H-2 q immunoaffinity columns (28-14-8S and 34-1-2S). Previous literature suggests that the 28-14-8S antibody can crossreact with both H-2D q and H-2L q . To prevent the co-elution of H-2D q and H-2L q peptides from undermining our analysis, we used the sequence available in the public domain for H-2L q (GenBank AAA39573.1) and compared it to the sequence obtained for H-2D q . We indeed find differences in the residues contained in the H-2 peptide-binding domain. These differences suggest subtle variation in the predicted ligands of H-2D q and H-2L q , allowing eluted peptides to be sorted using the Gibbs Cluster analysis. Only the peptides matching the H-2D q motif generated from the sMHC approach were used to validate NetH2pan. Additionally, we found that 34-1-2S also recognized H-2D q , because LC/MS analysis solved H-2D q peptides and H-2D q heavy chains in the eluate. Peptides eluted from 34- Table S3 ).
The list of tumor-presented peptides is accessible through IEDB, and specific MS/MS spectra are available upon request (Submission ID 1000724, http://www.iedb.org). Using the H-2 q peptides extracted from PyMT tumors, two dominant motifs emerged ( Fig. 3A and B ) that were nearly identical to the sMHC eluted and predicted motifs ( Figs. 1 and 2) . Of the 2000 tumor-eluted peptides, 27 cancer-associated source proteins were identified and used to test the prediction performance of NetH2pan vs. NetMHCpan-3.0 ( Fig. 3C , Supplementary Table S4 ). These 27 source proteins include oncogenes, tumor suppressors, and common biomarkers, but are not canonical "tumor antigens". The spectra of three (of twenty-seven) cancer-associated peptides, macrophage inhibitory factor (MIF), epithelial cell adhesion molecule (EpCAM), and hepatocyte growth factor receptor (MET), are shown to illustrate the unambiguous proteomic data obtained directly from tumors ( Fig. 3D-F) . The source protein sequences were subjected to NetH2pan and NetMHCpan-3.0 peptide predictions, then the identified eluted peptide was compared to the resulting predicted peptides. Pooling all sequences of the cancer-associated proteins containing at least one H-2D q ligand and digesting them in all possible 8-to 11-mers, resulted in a total of 86,340 peptides. The 32 observed H-2D q ligands constituted 0.04% of the total pool of 86,340 potential ligands, a number not too distant from the 0.1% estimate assumed in earlier studies [17, 28] . Among the top 32 ligands predicted by NetH2pan, 11 were true positives (PPV=34.4%). In contrast, none of the top 32 ligands predicted by NetMHCpan-3.0 were true positives. In sum, NetH2pan outperformed NetMHCpan on the peptide predictions, providing improved predicted binding affinities (Rank scores) ( Fig. 3C ). Of the 33 peptides, 32 were predicted within the top Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on April 3, 2018; DOI: 10.1158/2326-6066.CIR-17-0298 3%, with the median absolute rank being 3. In comparison, NetMHCpan predictions had a median absolute rank of 38. This means that when using NetH2pan, researchers are likely to find the true ligands by synthesizing only 3 predicted peptides, in contrast to the 38 required using the earlier NetMHCpan tool.
Discussion
In summary, we sequenced the MHC class I loci of FVB mice, produced and isolated their MHC class I proteins, and generated an MHC class I binding motif for the FVB "q" haplotype. Over 8500 ligands were eluted, allowing us to design a prediction tool for antigens of interest. This tool, "NetH2pan," improves on previous "NetMHCpan" methods by utilizing both binding affinity and elution mouse H2 data to generate its predictions, representing a sophisticated peptide modelling tool for mice. To confirm this, peptides directly identified on MMTV-PyMT primary tumors served as a validation of the predictive power of NetH2pan. This immunopeptidomics study represents the first MHC peptide characterization and prediction for the "q" haplotype and for MMTV-PyMT tumors. Our data also facilitates improved predictions of peptide presentation in other commonly used murine strains, including C57/BL6 and BALB/c. Antigen-specific T-cell responses have been difficult to study in breast cancer because the antigens are poorly characterized in mouse models with high penetrance of breast cancer. Our goal was to enable studies of antigen-specific responses in models of spontaneous tumor development and metastasis, which are often on the FVB background. Here, the identification of ligands directly eluted from tumors identifies MMTV-PyMT tumor-presented peptides, although immunogenicity studies must be undertaken to validate ligands as T-cell targets. This approach is not confined to a single antigen or murine strain, as we have provided a method improved from the NetMHCpan tool to predict peptides across several MHC Class I haplotypes. In this way, NetH2pan will be particularly useful for cancer neoepitope prediction from tumor-specific mutations identified via whole-exome-sequencing (WES) data in C57/BL6 tumor models, as the H-2 b predictions are now more likely to generate truly presented peptides [29] . This WES-tumor neoantigen-peptide prediction pipeline has been adopted and successfully used to treat human melanoma patients [1] .When used appropriately and in combination with WES data from tumors, NetH2pan can predict CD8 T-cell immune epitopes with fewer false positives. More work must be done to characterize which of these peptides are unique to the tumor and capable of activating CTLs. These studies are now feasible in more murine cancer models. The prediction model developed in this study is publicly available online as a webserver at: http://www.cbs.dtu.dk/services/NetMHCpan-4.0/NetH2pan.
Table 1. Cross-validated performance in AUC for prediction methods trained on binding affinity data only (BA), eluted ligands only (EL) and a combination of both data types (NetH2pan).
For binding affinity measurements, positive instances are defined as having an IC 50 affinity < 500nM. For elution assays, the total number of data points (N) includes the positives (i.e. the observed ligands) and a uniform distribution of artificial negatives generated as described in Materials and Methods. This tool predicts two properties of each peptide; binding affinity or eluted ligand likelihood. For binding affinity evaluation, the binding affinity predictions were used, and for eluted ligands, the eluted ligand likelihood predictions. 
